BL-M08D1
Sponsors
Sichuan Baili Pharmaceutical Co., Ltd.
Conditions
Diffuse Large B-Cell LymphomaGastrointestinal TumorsGynecological TumorsHead and Neck Squamous Cell CarcinomasNasopharyngeal Carcinoma (NPC)Relapsed or Refractory Lymphoid MalignanciesSolid TumorSolid Tumors
Phase 1
A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors
RecruitingNCT06718621
Start: 2025-02-12End: 2027-06-01Target: 22Updated: 2026-04-14
A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies
RecruitingNCT06718634
Start: 2025-01-02End: 2027-12-01Target: 22Updated: 2026-01-21
A Study of BL-M08D in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
Not yet recruitingNCT07780318
Start: 2026-09-01End: 2028-12-01Target: 60Updated: 2026-08-27
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Gynecological Malignancies and Other Solid Tumors
Not yet recruitingNCT07793825
Start: 2026-09-01End: 2028-12-01Target: 90Updated: 2026-08-31
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma
Not yet recruitingNCT07818499
Start: 2026-09-01End: 2028-12-01Target: 204Updated: 2026-09-14
A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors
Not yet recruitingNCT07818486
Start: 2026-09-01End: 2028-12-01Target: 30Updated: 2026-09-14